Fig. 1

HBXIP contributes to TAM resistance in breast cancer. a Relapse-free survival analysis of TAM-treated ER+ breast cancer patients by the Kaplan-Meier plotter online resource (http://kmplot.com/analysis/). The plot was generated according to the HBXIP expression level (log-rank P = 0.021). b Immunoblotting analysis of HBXIP in MCF-7, T47D, and BT474 cells (lower panel) and the quantification of the intensity relative to β-actin (upper panel). c, d Cell viability assay in MCF-7 (c) and BT474 (d) cells treated with corresponding doses of TAM after being transiently transfected with the indicated plasmids or siRNAs. e, f Colony forming efficiencies of MCF-7 (e) and BT474 (f) cells treated with DMSO or TAM (1 μM) after being transiently transfected with the indicated plasmids or siRNA. g, h Growth curve and imaging (g), Ki67 (a cell proliferation marker) staining by IHC assay and the statistics of Ki67 positive cells (h) of the xenograft tumors derived from MCF-7-pCMV (called M-pCMV) or MCF-7-HBXIP (called M-HBXIP) cells (each group, n = 5). Scale bar, 50 μm. i, j Growth curve and imaging (i), Ki67 staining by IHC assay and the statistics of Ki67 positive cells (j) of the xenograft tumors derived from BT474-pSilencer-Random (called B-pSi-Random) or BT474-pSilencer-HBXIP (called B-pSi-HBXIP) cells (each group, n = 5). Scale bar, 50 μm. All experiments were repeated at least three times. Error bars represent ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed Student’s t test